Beta Thalassemia Differential Diagnoses
- Author: Kenichi Takeshita, MD; Chief Editor: Emmanuel C Besa, MD more...
Diagnostic Considerations
A major diagnostic consideration is to distinguish mild microcytic anemia due to beta-thalassemia carrier state versus other causes of microcytic anemia. Iron studies (iron, transferrin, ferritin) are useful in excluding iron deficiency and the anemia of chronic disorders as the cause of the patient's anemia. The Mentzer index is defined as mean corpuscular volume per red cell count. An index of less than 13 suggests that the patient has the thalassemia trait, and an index of more than 13 suggests that the patient has iron deficiency.
Alpha thalassemia is another known cause of mild microcytic anemia. Alpha thalassemia is characterized by genetic defects in the alpha-globin gene, and this variant has features similar to those of beta thalassemia. In contrast to beta-thalassemia minor (carrier) patients who have elevated levels of Hb A2 (2 alpha-globin chains complexed with 2 delta-globin chains), patients with alpha-thalassemia have normal levels of Hb. Establishing the diagnosis of the alpha-thalassemia trait is often a diagnosis of exclusion; definitive diagnosis requires measuring either the alpha-beta chain synthesis ratio or performing genetic tests of the alpha-globin cluster (using Southern blot or polymerase chain reaction [PCR] assay tests).
Unstable Hb levels and some types of red cell membrane disorders are other conditions to consider in the differential diagnosis of beta-thalassemia.
Differential Diagnoses
- Anemia of Chronic Disease and Renal Failure
- Lead Nephropathy
- Lead poisoning
- Sideroblastic Anemias
Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. Sep 29 2011;118(13):3479-88. [Medline].
Galanello R, Sanna S, Perseu L, Sollaino MC, Satta S, Lai ME, et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood. Oct 29 2009;114(18):3935-7. [Medline]. [Full Text].
Lucarelli G, Galimberti M, Polchi P. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. Sep 16 1993;329(12):840-4. [Medline]. [Full Text].
Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. Aug 13 1998;339(7):417-23. [Medline]. [Full Text].
[Guideline] Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. May 2008;93(5):741-52. [Medline].
Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin Chim Acta. Sep 2009;407(1-2):10-5. [Medline].
Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood. Apr 14 2011;117(15):3945-53. [Medline]. [Full Text].
Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature. Sep 16 2010;467(7313):318-22. [Medline].

